1. Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine
- Author
-
Luis Salleras, Sergi Hernández, Sonia Uriona, Juan José García-García, Mariona Fernández de Sevilla, Carmen Muñoz-Almagro, Gemma Codina, Magda Campins, Cristina Esteva, Alvaro Díaz, Angela Domínguez, Pilar Ciruela, Anna Solé-Ribalta, Fernando A. Moraga-Llop, Sebastià González-Peris, Johanna Martínez-Osorio, Conchita Izquierdo, and Ana María Planes
- Subjects
Serotype ,Pediatrics ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,Serogroup ,medicine.disease_cause ,Pneumococcal Infections ,Pneumococcal conjugate vaccine ,Pneumococcal Vaccines ,Conjugate vaccine ,Management of Technology and Innovation ,Streptococcus pneumoniae ,medicine ,Humans ,Prospective Studies ,Child ,education ,Mechanical ventilation ,education.field_of_study ,Vaccines, Conjugate ,business.industry ,Incidence (epidemiology) ,bacterial infections and mycoses ,medicine.disease ,Pneumonia ,Child, Preschool ,business ,medicine.drug - Abstract
BACKGROUND Invasive pneumococcal disease (IPD) is the most important bacterial infection in young children, and the introduction of pneumococcal conjugate vaccines has changed its presentation. This study compared the incidence, characteristics and serotype distribution of IPD before and after the introduction of the pneumococcal conjugate vaccine (PCV13). METHODS Prospective enrolment of patients with IPD aged less than 60 months and admitted to either of 2 tertiary care hospitals between January 2007 and December 2009 (pre-PCV13 period) and January 2012 and June-2016 (PCV13 period). RESULTS We identified 493 cases, 319 in the pre-PCV13 period and 174 in the PCV13 period. The incidence of IPD decreased from 89.7 to 34.4 casos per 100 000 habitantes ( -62%; P
- Published
- 2022
- Full Text
- View/download PDF